Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Judge Kavanaugh May Be Good US Supreme Court Pick For Pharma

Executive Summary

Supreme Court nominee may side with biopharma companies in agency disputes, but it's unclear how he will rule on patent and product liability cases scheduled for review next term.


Related Content

Trump Drug Pricing Plan Includes Part D Surprises, Challenges PBM Business Model
Inter Partes Patent Challenges Are Constitutional, US Supreme Court Rules
Does FDA Rejection Of Label Warning Shield Manufacturers From Tort Suits?
Liability Win For Industry As US Supreme Court Curtails Forum-Shopping
US Supreme Court Permits Earlier Biosimilar Launches; Penalty For Declining Patent Dance Uncertain
Biopharma Patent Disputes: Upheaval Likely As US Supreme Court Limits Litigation Venue
Supreme Court Upholds IPR Standard Making Patent Invalidation Easier; Will Congress Reverse?
Pay-For-Delay Deals May Be Smaller After Supreme Court Okays FTC Suits
Pre-emption After Supreme Court Ruling May Depend On How FDA Weighs Risk


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts